The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging
across many parts of Africa. Resistance to existing drugs was emerging, and many programs …

Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African
Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same …

“We have never had such a sophisticated arsenal of technologies for treating diseases, yet
the gap in health outcomes keep getting wider. This is unacceptable.” This claim was made …

Human African trypanosomiasis (HAT) or 'sleeping sickness 'is a neglected tropical disease
caused by the parasite Trypanosoma brucei. Novel models for funding pharmaceutical …

Parasitic protozoa comprise diverse aetiological agents responsible for important diseases
in humans and animals including sleeping sickness, Chagas disease, leishmaniasis …

African sleeping sickness is endemic in sub-Saharan Africa where the WHO estimates that
60 million people are at risk for the disease. Human African trypanosomiasis (HAT) is 100 …

African sleeping sickness is a fatal parasitic disease, and all drugs currently in use for
treatment have strong liabilities. It is essential to find new, effective, and less toxic drugs …

Parasitic diseases such as Kala azar (visceral leishmaniasis), Chagas disease (American
trypanosomiasis) and African sleeping sickness (human African trypanosomiasis) are …

Rhodesain, a cathepsin L-like cysteine protease of T. brucei rhodesiense, is considered a
potential target for the treatment of human African trypanosomiasis. Recent findings have …

The need for new drugs against tropical parasites such as Plasmodium falciparum and
Trypanosoma brucei is persistent since problems with resistance and toxicity are …